A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Trial · NCT06585787
Registered outcomes27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 27
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline in Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions (NPI-C: H+D) score | Up to Week 14 | |
| Secondary | Change from baseline in Clinical Global Impressions-Severity (CGI-S) scale | Up to Week 14 | |
| Secondary | Change from baseline in Neuropsychiatric Inventory-Clinician (NPI-C) Core score: Hallucination Domain | Up to Week 14 | |
| Secondary | Change from baseline in NPI-C Core score: Delusion Domain | Up to Week 14 | |
| Secondary | Change from baseline in NPI-C Core score: Agitation Domain | Up to Week 14 | |
| Secondary | Change from baseline in NPI-C Core score: Aggression Domain | Up to Week 14 | |
| Secondary | Change from baseline in NPI-C Agitation score | Up to Week 14 | |
| Secondary | Change from baseline in NPI-C Core score: Caregiver Distress Scale | Up to Week 14 | |
| Secondary | Number of participants with a ≥ 40% improvement from Baseline in NPI-C: H+D score | Up to Week 14 | |
| Secondary | Number of participants with Adverse Events (AEs) | Up to Week 14 | |
| Secondary | Number of participants with Treatment-Emergent Adverse Events (TEAEs) | Up to Week 14 | |
| Secondary | Number of participants with Serious Adverse Events (SAEs) | Up to Week 14 | |
| Secondary | Number of participants with TEAEs leading to study withdrawal | Up to Week 14 | |
| Secondary | Number of participants with procholinergic symptoms | Up to Week 14 | |
| Secondary | Number of participants with anticholinergic symptoms | Up to Week 14 | |
| Secondary | Number of participants with AEs of Special Interest (AESIs) | Up to Week 14 | |
| Secondary | Barnes Akathisia Rating Scale (BARS) Score | Up to Week 14 | |
| Secondary | Abnormal Involuntary Movement Scale (AIMS) Score | Up to Week 14 | |
| Secondary | Body Weight | Up to Week 14 | |
| Secondary | Body Mass Index (BMI) | Up to Week 14 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06585787/registered